Study of BBO-8520 for advanced KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that has a specific change called KRAS G12C mutation.
- Your cancer is advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have at least one tumor that can be seen on a scan.
- You are generally able to do daily activities with little to no help (ECOG 0-1).
- If you have had brain metastases, they must be treated and stable.
- You must not have had another cancer in the last 2 years (except for certain types like skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.